Sign In
25 Mar 2019 07:00
PDMR Dealing
LONDON, March 25, 2019 (GLOBE NEWSWIRE) -- Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that, on March 22, 2019, Mr. Piers Morgan, CFO of the Company, purchased 20,132 ordinary shares of 5 pence each in the Company (the “Ordinary Shares”) at a price of 64 pence per Ordinary Share and a total purchase price of £12,884.48 Following the acquisition, Mr. Morgan will have an interest in the Company of 113,207 Ordinary Shares, representing 0.11% of the Company’s issued share capital.
The purchase by Mr. Morgan brings the total purchases made by him this month to £32,884.46 and follows the purchases made by the Company’s Chairman, Dr. David Ebsworth, earlier this month totaling approximately £50,000.00.
The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |
| a) | Name | Piers Morgan |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Financial Officer |
| b) | Initial notification/Amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Name | Verona Pharma plc |
| b) | LEI | 213800EVI6O6J3TIAL06 |
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | ||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 5 pence each GB00BYW2KH80 | |
| b) | Nature of the transaction | Piers Morgan purchased 20,132 Ordinary Shares | |
| c) | Price(s) and volume(s) | Price(s) | Volume(s) |
| 64 pence per Ordinary Share | 20,132 Ordinary Shares | ||
| d) | Aggregated information - Aggregated volume - Price | N/A | |
| e) | Date of the transaction | 22 March 2019 | |
| f) | Place of the transaction | London Stock Exchange, AIM | |
For further information, please contact:
| Verona Pharma plc | Tel: +44 (0)20 3283 4200 |
| Jan-Anders Karlsson, Chief Executive OfficerVictoria Stewart, Director of Communications | info@veronapharma.com |
| Stifel Nicolaus Europe Limited (Nominated Adviserand UK Broker) | Tel: +44 (0) 20 7710 7600 |
| Stewart Wallace / Jonathan Senior / Ben Maddison |
Follow the stocks
